Think You Have A “Breakthrough” Drug? Think Again, FDA’s Woodcock Says
Executive Summary
CDER director says breakthrough designation requests are frequently denied because evidence suggests only an incremental advance over standard therapy; other reasons for denial include showing no clinical advantage and a development program being placed on clinical hold.
You may also be interested in...
“Breakthrough” Review: FDA And Sponsors Discuss Ways To Improve Efficiency
Pharmacyclics exec says PDUFA V “program” meetings should be optional, as timelines for mid-cycle communication and late-cycle meeting are out of sync with highly compressed review times for some products. CDER is internally discussing whether it would be feasible to give breakthrough therapy sponsors a target date for approval.
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.
ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages
ADHD drug shortages may have resulted from industry reticence to fill DEA quotas, as well as a 'heavy element of professional responsibility' with off-label prescribing, Robert Califf told a House appropriations subcommittee.